Background: Due to its potent effects on social behavior, including maternal behavior, oxytocin has been identified as a potential mediator of postpartum depression and anxiety. The objective of this study was to examine the relationship between peripartum synthetic oxytocin administration and the development of depressive and anxiety disorders within the first year postpartum. We hypothesized that women exposed to peripartum synthetic oxytocin would have a reduced risk of postpartum depressive and anxiety disorders compared with those without any exposure.
INTRODUCTION
Postpartum depressive and anxiety disorders are diagnosed in up to 12.9 and 20.4% of women, respectively (Austin et al., 2010; Gaynes et al., 2005; Reck et al., 2008; Vesga-Lopez et al., 2008) , and adversely affect mothers and their offspring (Earls, 2010; Goodman, 2007) . Postpartum depression has an effect on maternal functioning and can be fatal; maternal suicide accounts for up to 20% of deaths in depressed postpartum women (Lindahl, Pearson, & Colpe, 2005) . For offspring, maternal postpartum depression is associated with difficult infant and childhood temperament (Britton, 2011; Feldman et al., 2009 ), attachment insecurity (Forman et al., 2007) , developmental delays (Deave, Heron, Evans, & Emond, 2008) , changes in cognitive development (Azak, 2012; Murray & Cooper, 1997; Sohr-Preston & Scaramella, 2006) , and difficulties with social interaction (Downey & Coyne, 1990 ).
Postpartum anxiety is associated with infant irritability, poor infant sleep, and breastfeeding difficulty (Jover et al., 2014) .
Despite negative impacts on both mother and child, the pathophysiology of postpartum depressive and anxiety disorders is poorly understood, with relatively few animal models (Perani & Slattery, 2014) .
Due to its role in the modulation of social behavior, especially affiliative bonding, oxytocin has been identified as a potential mediator of postpartum depression and anxiety (Kim et al., 2014) . Animal studies document a relationship between oxytocin and expressions of normal maternal behavior (Finkenwirth, Martins, Deschner, & Burkart, 2016; Nephew, 2012; Rilling & Young, 2014) , as well as with animal models of postpartum psychiatric disorders (Babb, Carini, Spears, & Nephew, 2014; Murgatroyd & Nephew, 2013; Perani & Slattery, 2014) and the effects of labor induction on offspring neural development (Hashemi et al., 2013) . This preclinical literature suggests that the use of synthetic oxytocin in the peripartum period may have long-term effects on mood in both mothers and their offspring and led to the recent introduction of oxytocin manipulations as potential therapeutic targets for the treatment of postpartum psychiatric disorders (Bell, Erickson, & Carter, 2014; Kim et al., 2013; Strathearn, 2011) .
In humans, maternal plasma levels of oxytocin are associated with maternal gaze, vocalizations, and affectionate contact , as well as maternal representations of attachment (Bell et al., 2014; . Two clinical studies have found that low antepartum blood oxytocin levels are correlated with postpartum depression (Skrundz, Bolten, Nast, Hellhammer, & Meinlschmidt, 2011; Stuebe, Grewen, & Meltzer-Brody, 2013) , and related work reports an association between prepartum depression and low oxytocin (Garfield et al., 2015) . Genetic analyses indicate that postpartum depression may be mediated by epigenetic variation in oxytocin receptor expression (Bell et al., 2015) , and a similar relationship is observed in nonmaternal depressed women (Reiner et al., 2015) .
Failed lactation (Stuebe, Grewen, Pedersen, Propper, & Meltzer-Brody, 2011 ) and symptoms of depression are associated with differences in oxytocin activity (Stuebe et al., 2013) , and it has been postulated that endogenous oxytocin may protect against the adverse depressive effects of psychosocial stress on mothers (Zelkowitz et al., 2014) . A recent review underscores the importance of reproductive and perinatal stage in associations between oxytocin and depression (Massey, Backes, & Schuette, 2016) . Despite these clinical observations and interest in oxytocin as a treatment for perinatal depression and anxiety, there has been little investigation of the potential effects of clinical peripartum manipulation through the use of synthetic oxytocin.
Synthetic oxytocin has been used since the 1950s (Fields, Greene, & Franklin, 1959) , and current indications for use include labor induction or augmentation and prevention or treatment of postpartum hemorrhage ("ACOG Practice Bulletin No. 107: Induction of labor," ACOG, 2009). Between 1990 and 2012, rates of labor induction increased from 9.5 to 23.3% , with rates as high as 42% in some populations (Laughon et al., 2012) . Rates of labor augmentation are estimated at 57% (Declercq, Sakala, Corry, & Applebaum, 2007) . However, recent recommendations, including those from the World Health Organization, indicate the use synthetic oxytocin as the first line agent in the active management of the third stage of labor for hemorrhage prevention (Westhoff, Cotter, & Tolosa, 2013; WHO, 2012) , and it is conceivable that most or all women giving birth will soon have some synthetic oxytocin exposure.
The objective of this study was to examine the relationship between peripartum synthetic oxytocin administration and the development of depressive and anxiety disorders within the first year postpartum. We hypothesized that women exposed to peripartum synthetic oxytocin would have a reduced risk of postpartum depressive and anxiety disorders compared with those without exposure. To retrospectively examine this relationship, we utilized population-based data available through the Massachusetts Integrated Clinical Aca- 
METHODS

Study design and data source
This was an analysis of data from a clinical data repository of patients who delivered a single live born infant at UMMHC between January 2, 2005 and April 4, 2014. Protected health information (PHI) was accessed using individual medical record numbers provided by the MiCARD query tool, the UMMHC implementation of the Informatics for Integrating Biology & the Bedside (i2b2) platform for clinical research (Murphy et al., 2010 
Study sample
Participants were identified at the delivery level, where each delivery was considered a separate unit in our analysis. Deliveries were selected based on the following inclusion criteria: live born singleton deliveries, coded with any of the eligible delivery codes (Table 1) , to females between the ages of 15 and 50. Multiple gestation deliveries (i.e., twins, triplets, or higher order multiples) were excluded from the study. Deliveries were identified using Current Procedural
Terminology (CPT) and International Classification of Diseases 9th
Revision (ICD-9) diagnosis codes. We considered the first delivery to each woman in our dataset as her "index delivery." Depression and anxiety data included any diagnosis information and/or documentation of clinically relevant antidepressant or anxiolytic medication prescription (Table 1) Initially, data were set up longitudinally where each delivery could exist across many records due to multiple diagnosis codes assigned to any one delivery. We removed any delivery records that had the same patient ID, event date, delivery code, and treatment (±synthetic oxytocin). This excluded 17,584 delivery records. CPT and ICD-9 delivery codes are conventionally used to designate deliveries that occur after 20 weeks gestational age, as deliveries occurring prior to 20 weeks gestation are considered abortions, whether spontaneous, elective, therapeutic, or otherwise. As a pregnancy due date is based on 40 weeks gestation but some can extend post-dates with the vast majority being delivered by 42 weeks gestation, we considered a "birth interval" to minimally be 22 weeks (154 days) between delivery dates for each unique ID. Any delivery codes that existed within 154 days of each other for the same woman were considered part of the same delivery. After applying this birth interval filter, we excluded an additional 43,254 delivery records, likely part of the same delivery or hospital stay with delivery codes recorded on multiple/subsequent days. Finally, we excluded any records not meeting our eligibility criteria that were not flagged upon initial data query. This removed 532 deliveries where the maternal age at delivery was less than 15 and 861 deliveries where the maternal age at delivery was greater than 50.
Our final analytic sample included 46,732 unique deliveries (from 35,978 women); 37,048 deliveries without peripartum synthetic oxytocin exposure and 9,684 deliveries with peripartum synthetic oxytocin exposure (Fig. 1) . The delivery and psychiatric datasets were merged using an individual patient identifier available across datasets.
Quantitative variables
We classified depressive or anxiety disorders, defined as record of diagnosis and/or receipt of antidepressant or anxiolytic medication prescription, into three timeframes: prepregnancy: diagnoses/prescriptions greater than one year prior to the index delivery (diagnosis/prescription prior to (delivery date -365 days)); pregnancy: diagnosis/prescription during pregnancy, or occurring between 40 weeks prior to delivery date (delivery date -280 days) and delivery date; and postpartum: diagnosis/prescription one year following delivery (delivery date + 365 days) or 280 days between multiple deliveries (delivery date + 280 days). We retained any depressive or anxiety diagnosis or receipt of psychotropic medication prescription with a service date falling within any of these windows.
Psychiatric diagnosis ICD-9 codes were grouped into categories for analysis: (1) Adjustment disorder (various types) (309, 309.1, 309.24, 309.28, 309.89, 309.9) ; (2) depressive disorder-not otherwise specified (NOS) (311); (3) major depressive disorder (MDD), various types (296.2, 296.21, 296.22, 296.23, 296.24, 296.25, 296.26, 296.3, 296.31, 296.32, 296.33, 296.34, 296.35, 296.36) ; (4) episodic mood disorder (296.99); (5) anxiety states (300.09); (6) generalized anxiety disorder (GAD) (300.02); (7) anxiety disorder-not otherwise specified (NOS) (300.00); (8) posttraumatic stress disorder (PTSD) (309.81); and (9) panic disorder, with or without agoraphobia (300.01). Codes for adjustment disorders were included in the analysis due to variations in coding practices (Fiest et al., 2014) . We examined the frequency of depressive or anxiety disorders in each of our three timeframes.
Additionally, we created a flag to distinguish caesarean and vaginal deliveries in the 24,099 delivery records coded with at least one CPT code. Caesarean deliveries were indicated with CPT codes 59510, 59514, 59515, 59618, 59620, and 59622; vaginal deliveries with CPT codes 59400, 59409, 59410 59610, 59612, and 59614.
Finally, we included the following covariates to examine descriptively, for our total sample as well as by oxytocin exposure group: maternal age, marital status (single, married, divorced/separated, and widowed), and race and ethnicity, all recorded at the time of data pull (October 2015), with the exception of maternal age that was recorded at the time of the event. We also included year of delivery grouped into 5-year intervals as an additional covariate.
Statistical analysis
As our primary interest was to examine the association between oxytocin exposure and postpartum depressive or anxiety disorder, we TA B L E 1 Billing, drug, and procedure codes for obstetric deliveries, oxytocin administration, depressive or anxiety disorders, diagnoses, and medications
Condition
ICD-9 code CPT code Date of first record in database
Deliveries 650, V27.0 59400, 59409, 59410, 59510, 59514, 59515, 59525, 59610, 59612, 59614, 59618, 59620, 59622 6 April, 1995 Depressive or anxiety disorder diagnosis 309. 00, 309.10, 309.24, 309.28, 309.90, 309.89, 309.81, 311.00 296.30, 296.31, 296.32, 296.33, 296.34, 296.35, 296.36, 296.20, 296.21, 296.22, 296.23, 296.24, 296.25, 296.26, 296.90, 296.99 Additionally, we conducted sensitivity analyses to examine the robustness of our initial findings. We replicated our analysis on our total sample in two subsets: first, by selecting a random delivery from each woman in our sample; and next, by repeating our analysis on all index deliveries (as available in the database), regardless of prepregnancy depressive or anxiety disorder history. We also repeated our analyses to examine the effect of depression or anxiety disorders diagnosed during pregnancy. Finally, we varied the 40-week definitions for our pregnancy and postpartum timeframes to 37 and 42 weeks (259 and 294 days, respectively). This was done to account for the vast majority of range of deliveries given our inability to determine gestational age at delivery.
All analyses were conducted in SAS Version 9.3 (SAS Institute, Inc., Cary, North Carolina).
RESULTS
Descriptive data
The average onset of postpartum depressive and anxiety symptoms in patients who received a diagnosis or prescription was 112.52 days (±standard deviation 111.35). The median amount of time between delivery and diagnosis/prescription receipt was 71 days, suggesting that 50% of our patients received their diagnosis/prescription within just over 2 months following delivery. Descriptive data can be found in Figure 1 and Table 2 .
Main results
Results from the risk comparison models showed that RR and their associated 95% confidence intervals (95% CI) were higher in women with peripartum exposure to synthetic oxytocin across all subgroups (Fig. 2) . In index deliveries to women with a history of prepregnancy depressive or anxiety disorder (or documentation of antidepressant (Table 3 ). In deliveries to women with no history of prepregnancy depressive or anxiety disorder, exposure to peripartum oxytocin increased the risk of postpartum depressive or anxiety disorder by 32% compared to those not exposed to peripartum oxytocin (RR: 1.32; 95% CI: 1.23-1.42) ( Table 4 ).
In index deliveries to women with a history of prepregnancy depressive or anxiety disorder, the RR of postpartum depressive or anxiety disorder was higher in women who received peripartum synthetic oxytocin compared to those who did not for both vaginal (RR: 1.45; 95% CI: 1.22-1.72) and cesarean (RR: 1.38; 95% CI: 1.00-1.91) deliveries.
In deliveries to women with no history of prepregnancy depressive or anxiety disorder, exposure to synthetic oxytocin increased the RR of postpartum depressive or anxiety disorder by 19% in vaginal deliveries and 25% in cesarean deliveries compared to those not exposed (RR:
1.19; 95% CI: 1.07-1.32 and RR: 1.25; 95% CI: 1.05-1.49, respectively.
Data not shown.)
Sensitivity analyses
When selecting a random delivery from each woman, regardless of prepregnancy depressive or anxiety disorder history, the RR of postpartum depressive or anxiety disorder was 35% higher in women who received peripartum synthetic oxytocin compared to those who did not 
TA B L E 3
Relative risks and 95% confidence intervals comparing risk for postpartum depressive or anxiety diagnosis or psychotropic medication and peripartum exposure to oxytocin for index deliveries to women with a history of prepregnancy depressive or anxiety diagnosis or psychotropic medication (n = 3,609) deliveries from the main analysis resulted in a RR of 1.41 (95% CI:
1.32-1.51), confirming that episodes during pregnancy did not influence our findings.
Lastly, examining the full-term delivery spectrum of 37-42 weeks did not change the results (data not shown).
DISCUSSION
Contrary to our hypothesis, our results indicate that women with peripartum exposure to synthetic oxytocin had a higher RR of receiving a documented depressive or anxiety disorder diagnosis or F I G U R E 2 Relative risks and 95% confidence intervals comparing risk for postpartum depressive or anxiety diagnosis or psychotropic medication and peripartum exposure to oxytocin by delivery type and history of prepregnancy depressive or anxiety diagnosis or psychotropic medication antidepressant/anxiolytic prescription within the first year postpartum than women without synthetic oxytocin exposure. This increased risk was still present when the analyses were restricted to index deliveries or a single random delivery in women who had multiple deliveries, and the risks were higher regardless of delivery mode.
The literature on the role of endogenous oxytocin concentrations and synthetic oxytocin administration in the peripartum period on postpartum mood is scarce, and data are conflicting. Several studies have examined the relationship between maternal plasma oxytocin and depressive symptomology (Cox et al., 2015; Garfield et al., 2015; Skrundz et al., 2011; Stuebe et al., 2013) . Three of these studies (Garfield et al., 2015; Skrundz et al., 2011; Stuebe et al., 2013) found that low oxytocin during pregnancy is associated with increased depressive symptoms and thus suggest that administering exogenous oxytocin, such as the synthetic oxytocin Pitocin, may alleviate or prevent negative postpartum mood. Another study found lower oxytocin levels during breastfeeding at 8 weeks postpartum in women with depressive symptoms compared to asymptomatic women (Cox et al., 2015) . However, one study found that higher oxytocin in the third trimester predicted higher depressive symptom severity at 6 weeks postpartum, but only in women with a prior history of depression; plasma oxytocin was unrelated to symptom severity in women without a history of depression . And finally, a very recent longitudinal study of women whose plasma oxytocin was measured twice during pregnancy and at three different times postpartum, found that rather than absolute plasma oxytocin levels, the timing of fluctuations in oxytocin levels from pregnancy to 6 months postpartum differed significantly in women with postpartum depressive symptoms compared to those without (Jobst et al., 2016) .
Even fewer studies have addressed the effects of administration of oxytocin on postpartum mood. A randomized controlled trial (RCT)
that investigated the effect of timing of intravenous administration of oxytocin in primiparous laboring women with dysfunctional labor indicated that women who received oxytocin earlier in their labor had a nonsignificant, but higher rate of major depression, although median depression scores did not differ between groups (Hinshaw, Simpson, Cummings, Hildreth, & Thornton, 2008) . Another RCT administered intranasal synthetic oxytocin in a placebo-controlled, double-blind, within-subjects design to a cohort of mothers diagnosed with postpartum depression (Mah, Van Ijzendoorn, Smith, & Bakermans-Kranenburg, 2013) , and treatment resulted in lower reported mood. Our data support the idea that synthetic oxytocin administration during labor has a negative impact on postpartum mood. It is important to note that the effect of synthetic oxytocin administration on endogenous oxytocin levels is unclear, and nothing about endogenous oxytocin levels can be inferred from our dataset and the aforementioned RCTs. For example, it is possible that low endogenous oxytocin is associated with both the need for synthetic oxytocin administration during labor and higher postpartum depressive symptomatology. One recent study, however, found that the dose of synthetic oxytocin given during the labor and delivery (as determined retroactively from hospital charts) was positively correlated with both endogenous levels of oxytocin and depressive symptoms at 2 months postpartum (Gu et al., 2016) , similar to the results from intravenous dosing. The current data suggest that peripartum synthetic oxytocin administration may have more prolonged negative effects on mood than demonstrated in the aforementioned studies, where depression symptoms following treatment were only measured at a single time point soon after administration.
Strengths of the present investigation include a reasonable sample size and a diverse population. Inclusion of both diagnostic and medication prescription codes acknowledges the importance of assessing both diagnoses and symptoms, in line with Research Domain Criteria (RDoC) initiative (Insel et al., 2010) . The sensitivity analyses also indicate that this association is found across different parous states and within the full-term delivery spectrum. As an initial investigation of associations between peripartum synthetic oxytocin and maternal mood and anxiety, it provides a theoretical and methodological framework for both expanded and more specific studies of this relationship.
For example, similar medical databases searches that include Medicaid patients and/or more detailed data on Pitocin exposures would be beneficial, as well as longitudinal studies, which assess oxytocin levels and mood at multiple peripartum time points. The use of the i2b2 informatics platform makes this especially relevant to the dozens of institutions that have access to this resource, increasing the potential for future multisite investigations. This broad examination of maternal depression and anxiety during the first year postpartum extends beyond the previous investigations that only focused on the early postnatal period, including a more expansive assessment of risk that reflects growing concerns about the prevalence and adverse effects of postpartum depression throughout the first year and beyond (ACOG, 2015) .
A few limitations of the study affect the interpretation of the results and potential applicability of the findings. The effects of Pitocin on oxytocin levels could not be assessed. Given that these are administrative/population health data, it is not possible to determine whether the relationship between peripartum synthetic oxytocin administration and postpartum depressive and anxiety disorders is causal. True prevalence of postpartum depressive and anxiety disorders is likely underestimated due to known underdiagnosis and thus underdocumentation in the medical record (Evins, Theofrastous, & Galvin, 2000; Halbreich & Karkun, 2006 Barton, PhD for his assistance with statistical analyses.
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